title: Using a silver-coated polymeric substrate for the management of chronic ulcerations: the initial Mayo Clinic experience.
abstract: BACKGROUND
  This retrospective observational study was designed to review the use of a silver-coated polymeric substrate on various types of chronic wounds at the Mayo Clinic in Rochester, Minnesota.
  
  
  METHODS
  The study was set in a community and referral multidisciplinary vascular wound clinic. The authors identified the first 112 patients treated with a silver dressing in the center. Of these, 15 were lost to follow-up or had incomplete data. Ninety-seven patients were included in the study. Thirty-seven of these 97 patients had multiple wounds; however, 1 wound per person was randomly chosen for analysis. The median age of these patients was 69 years. A wound was considered healed when the wound was completely epithelialized. Of the 97 wounds evaluated, the primary etiologies were as follows: 20 (20.6%) were neurotrophic, 24 (24.7%) were ischemic (arterial, arteriolar, or vasculitic), 20 (20.6%) were venous, 7 (7.2%) were traumatic, and 16 (16.5%) were multifactorial. The silver dressing was the primary wound care product on all wounds. Silverlon (Argentum LLC, Chicago, Illinois) was the silver dressing used for this study. The frequency of dressing changes and use of secondary dressings, to keep the wound moist, were based on the amount of drainage, debris, and slough on the wound. Data pertaining to patient demographics, risk factors, wound etiology, noninvasive arterial vascular studies, frequency of dressing changes, wound discomfort, wound size, and wound duration were collected by retrospective chart review.
  
  
  RESULTS
  Thirty-five of the 97 wounds (36.1%) healed. The 62 nonhealed wounds (63.9%) decreased in size by a median of 55.2%. Among the 68 patients who had reported discomfort before the study, 77.9% reported no change in discomfort, 17.7% reported increased pain, and 4.4% reported decreased pain.
  
  
  CONCLUSIONS
  A silver-coated polymeric substrate (Silverlon) can be used as an effective primary wound care dressing in patients with active wounds.
authors.affiliation: Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, USA.
authors.forename: Rusty A
authors.initials: RA
authors.lastname: Moore
authors.forename: David A
authors.initials: DA
authors.lastname: Liedl
authors.forename: Sarah
authors.initials: S
authors.lastname: Jenkins
authors.forename: Karen L
authors.initials: KL
authors.lastname: Andrews
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care / Q000379:methods; D000554:Ambulatory Care Facilities; D002908:Chronic Disease; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007871:Leg Ulcer / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009779:Occlusive Dressings; D010147:Pain Measurement; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D012834:Silver / Q000627:therapeutic use*; D017592:Skin Care / Q000379:methods; D012883:Skin Ulcer / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D016896:Treatment Outcome; D014945:Wound Healing / Q000502:physiology*
chemical_list: C500574:silverlon; D012834:Silver